You just read:

Vantia Therapeutics Announces Positive Results From its Phase III EQUINOC Study, a Pivotal Trial with Fedovapagon for the Treatment of Nocturia in Men with Benign Prostatic Hyperplasia

News provided by

Vantia Therapeutics

03 Oct, 2017, 12:00 BST